Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | ACACB | O00763 | 4/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22567502 | 1.00 | MEN1 (0.36) | MEN1KMT2AACACBJAK2JAK1 | |
| SCHEMBL22567303 | 1.00 | MEN1 (0.36) | MEN1KMT2AACACBJAK2JAK1 | |
| SCHEMBL22555789 | 0.85 | ACACB (0.37) | MEN1KMT2AACACBTSHRGAA | |
| SCHEMBL22567581 | 0.85 | ACACB (0.37) | MEN1KMT2AACACBTSHRGAA | |
| SCHEMBL22567362 | 0.85 | ACACB (0.37) | MEN1KMT2AACACBTSHRGAA | |
| Hydrochloric Acid SCHEMBL22555742 | 0.84 | KMT2A (0.36) | MEN1KMT2AACACBTSHRGAA | |
| SCHEMBL21963786 | 0.84 | TP53 (0.40) | MEN1KMT2ATSHRGAAALDH1A1 | |
| SCHEMBL20898275 | 0.82 | FKBP1A (0.38) | MEN1KMT2ATSHRGAAALDH1A1 | |
| SCHEMBL20898311 | 0.81 | KDM4E (0.35) | JAK2JAK1ALDH1A1 | |
| SCHEMBL22567429 | 0.81 | KDM4E (0.35) | JAK2JAK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11325915-B2 | Lysyl oxidase inhibitors | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2022-05-10 | — | — | US | disclosed |
| US-20200331922-A1 | LYSYL OXIDASE INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2020-10-22 | — | — | US | disclosed |
| WO-2019073251-A1 | LYSYL OXIDASE INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2019-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331922-A1 | LYSYL OXIDASE INHIBITORS | LOXL1, LOXL2, LOXL3 | MEN1 4491/4885KMT2A 2125/4885ACACB 866/4885 |
| US-11325915-B2 | Lysyl oxidase inhibitors | LOXL1, LOXL2, LOXL3 | MEN1 4491/4885KMT2A 2125/4885ACACB 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.